SG10201604354XA - Antisense compounds targeted to connexins and methods of use thereof - Google Patents

Antisense compounds targeted to connexins and methods of use thereof

Info

Publication number
SG10201604354XA
SG10201604354XA SG10201604354XA SG10201604354XA SG10201604354XA SG 10201604354X A SG10201604354X A SG 10201604354XA SG 10201604354X A SG10201604354X A SG 10201604354XA SG 10201604354X A SG10201604354X A SG 10201604354XA SG 10201604354X A SG10201604354X A SG 10201604354XA
Authority
SG
Singapore
Prior art keywords
connexins
methods
antisense compounds
compounds targeted
targeted
Prior art date
Application number
SG10201604354XA
Inventor
Wilda Laux
Colin R Green
Original Assignee
Coda Therapeutics Nz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics Nz Ltd filed Critical Coda Therapeutics Nz Ltd
Publication of SG10201604354XA publication Critical patent/SG10201604354XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG10201604354XA 2003-12-03 2004-12-03 Antisense compounds targeted to connexins and methods of use thereof SG10201604354XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ52993603 2003-12-03

Publications (1)

Publication Number Publication Date
SG10201604354XA true SG10201604354XA (en) 2016-07-28

Family

ID=34651584

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012088225A SG187381A1 (en) 2003-12-03 2004-12-03 Antisense compounds targeted to connexins and methods of use thereof
SG10201604354XA SG10201604354XA (en) 2003-12-03 2004-12-03 Antisense compounds targeted to connexins and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012088225A SG187381A1 (en) 2003-12-03 2004-12-03 Antisense compounds targeted to connexins and methods of use thereof

Country Status (17)

Country Link
US (6) US8034789B2 (en)
EP (3) EP1699924B1 (en)
JP (5) JP5838017B2 (en)
KR (5) KR101359741B1 (en)
CN (3) CN103212088B (en)
AU (4) AU2004294824A1 (en)
CA (2) CA3059497A1 (en)
DK (1) DK1699924T3 (en)
EA (2) EA015670B9 (en)
ES (1) ES2749374T3 (en)
HK (1) HK1257506A1 (en)
HU (1) HUE045953T2 (en)
IL (2) IL176067A (en)
NZ (1) NZ548204A (en)
SG (2) SG187381A1 (en)
WO (1) WO2005053600A2 (en)
ZA (1) ZA200605305B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187381A1 (en) 2003-12-03 2013-02-28 Coda Therapeutics Nz Ltd Antisense compounds targeted to connexins and methods of use thereof
AU2005319155B2 (en) 2004-12-21 2013-01-31 Musc Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
AU2016203204A1 (en) * 2005-02-03 2016-06-09 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
JPWO2007055224A1 (en) * 2005-11-08 2009-04-30 関西ティー・エル・オー株式会社 Treatment for corneal diseases
KR20100027091A (en) * 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
ES2527131T3 (en) 2006-12-11 2015-01-20 Coda Therapeutics, Inc. Antonexin polynucleotides as compositions for altered wound healing
JP5552048B2 (en) * 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント Alpha-connexin C-terminal (ACT) peptide for treating age-related macular degeneration
CN102105492A (en) * 2007-12-11 2011-06-22 科达治疗公司 Impaired wound healing compositions and treatments
CA2710227A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of surgical adhesions
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
WO2009085275A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
EP2240583A2 (en) * 2008-01-07 2010-10-20 Coda Therapeutics, Inc. Wound healing compositions and treatments
US9173896B2 (en) * 2008-02-15 2015-11-03 Arrowhead Research Corporation RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
WO2009148552A2 (en) * 2008-06-02 2009-12-10 Kansas State University Research Foundation Methods and compositions for treating disease
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
AU2013225716B2 (en) 2012-03-01 2017-10-12 Xequel Bio, Inc. Topical gels containing alpha connexin C-terminal (ACT) peptides
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc Removal of dna fragments in mrna production process
PL3019619T3 (en) 2013-07-11 2022-01-10 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
CN106659909B (en) 2013-08-21 2022-01-11 德克萨斯州大学系统董事会 Compositions and methods for targeting connexin hemichannels
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
KR20160110370A (en) * 2013-12-04 2016-09-21 알엑스아이 파마슈티칼스 코포레이션 Methods for treatment of wound healing utilizing chemically modified oligonucleotides
WO2015191795A1 (en) * 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
EP3183346A4 (en) * 2014-08-22 2018-10-24 Auckland Uniservices Limited Channel modulators
AU2016309948B2 (en) * 2015-08-14 2021-05-20 The University Of Sydney Connexin 45 inhibition for therapy
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
EP3419998A4 (en) 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
US11364259B2 (en) 2016-12-27 2022-06-21 The University Of Tokyo MRNA functionalization method
US11466069B2 (en) 2017-04-28 2022-10-11 Auckland Uniservices Limited Methods of treatment and novel constructs
JP2022522247A (en) * 2019-02-08 2022-04-14 オークランド ユニサービシズ リミテッド Biomaterials and related methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
FR2692265B1 (en) 1992-05-25 1996-11-08 Centre Nat Rech Scient BIOLOGICALLY ACTIVE COMPOUNDS OF THE PHOSPHOTRIESTER TYPE.
GB2273932A (en) 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
CN1187774A (en) * 1995-04-19 1998-07-15 阿科达治疗所 CNS neurite out growth modulators, and compositions, cells and methods embodying and using same
CA2273203A1 (en) 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU776512B2 (en) * 1999-01-27 2004-09-09 David Laurence Becker Formulations comprising antisense nucleotides to connexins
IL140054A0 (en) * 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
CN1347902A (en) * 2000-10-11 2002-05-08 上海博德基因开发有限公司 New polypeptide human cartilage connecxin 14.19 and polynucleotides for encoding this polypeptide
SG187381A1 (en) 2003-12-03 2013-02-28 Coda Therapeutics Nz Ltd Antisense compounds targeted to connexins and methods of use thereof

Also Published As

Publication number Publication date
CN1922320B (en) 2013-04-24
AU2011200868A1 (en) 2011-03-17
EA015670B9 (en) 2012-01-30
HK1257506A1 (en) 2019-10-25
CA2547780C (en) 2019-10-22
US10174316B2 (en) 2019-01-08
IL244085B (en) 2018-02-28
US8815819B2 (en) 2014-08-26
JP5838017B2 (en) 2015-12-24
SG187381A1 (en) 2013-02-28
NZ548204A (en) 2009-08-28
CN103212088B (en) 2018-02-02
AU2017200049B2 (en) 2019-04-04
JP2011201926A (en) 2011-10-13
EA015670B1 (en) 2011-10-31
HUE045953T2 (en) 2020-01-28
KR101350837B1 (en) 2014-01-14
US20140371297A1 (en) 2014-12-18
US20120093768A1 (en) 2012-04-19
KR20150006902A (en) 2015-01-19
WO2005053600A3 (en) 2006-03-02
IL176067A (en) 2016-12-29
EA200601071A1 (en) 2006-12-29
JP2018104476A (en) 2018-07-05
ES2749374T3 (en) 2020-03-20
KR20070011260A (en) 2007-01-24
JP2007513148A (en) 2007-05-24
AU2004294824A1 (en) 2005-06-16
US11390870B2 (en) 2022-07-19
IL176067A0 (en) 2006-10-05
CN1922320A (en) 2007-02-28
US10787667B2 (en) 2020-09-29
DK1699924T3 (en) 2019-10-21
AU2011200868B2 (en) 2013-07-18
KR20180037067A (en) 2018-04-10
JP2016155869A (en) 2016-09-01
EA201100953A1 (en) 2012-03-30
US20070244062A1 (en) 2007-10-18
CN108175862B (en) 2022-02-08
KR101359741B1 (en) 2014-02-06
KR20130008653A (en) 2013-01-22
EA029094B1 (en) 2018-02-28
EP2314689A2 (en) 2011-04-27
EP1699924A2 (en) 2006-09-13
EP2311949A2 (en) 2011-04-20
CA2547780A1 (en) 2005-06-16
EP2314689A3 (en) 2012-12-19
ZA200605305B (en) 2007-04-25
US8034789B2 (en) 2011-10-11
CA3059497A1 (en) 2005-06-16
US10472632B2 (en) 2019-11-12
EP1699924B1 (en) 2019-09-04
US20200063136A1 (en) 2020-02-27
US20210079396A1 (en) 2021-03-18
JP2014122248A (en) 2014-07-03
EA029094B9 (en) 2018-04-30
AU2017200049A1 (en) 2017-02-02
IL244085A0 (en) 2016-04-21
CN108175862A (en) 2018-06-19
CN103212088A (en) 2013-07-24
EP2311949A3 (en) 2012-11-21
US20190194657A1 (en) 2019-06-27
KR20120034817A (en) 2012-04-12
AU2013245555A1 (en) 2013-11-07
WO2005053600A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
HK1257506A1 (en) Antisense compounds targeted to connexins and methods of use thereof
ZA200701846B (en) Monocot ahass sequences and methods of use
EP1639086A4 (en) Rna interferases and methods of use thereof
EG27049A (en) P38 inhibitors and methods of use thereof
GB2442373B (en) Sequence -specific inhibition of small rna function
EP1606285A4 (en) Novel ido inhibitors and methods of use
SI3611266T1 (en) Rna containing modified nucleosides and methods of use thereof
PL378432A1 (en) P38 inhibitors and methods of use thereof
IL176958A0 (en) Compounds and methods of use
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
ZA200600387B (en) Hydrolytically-resistant bornon-containing therapeutics and methods of use
EP1603567A4 (en) Tetracyclic benzamide derivatives and methods of use thereof
GB0325192D0 (en) Method of use
HK1084949A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP1812451A4 (en) Compounds and methods of use thereof
EP1625111A4 (en) Thyronamine derivatives and analogs and methods of use thereof
EP1633749A4 (en) Deazaflavin compounds and methods of use thereof
EP1625141A4 (en) Grp94-based compositions and methods of use thereof